Morgan Stanley Sab Biotherapeutics, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.62 - $1.0 $7,133 - $11,506	11,506 New	11,506 $7,000
Q4 2023 Feb 13, 2024	SELL	$0.62 - $1.0 $2,418 - $3,900	-3,900 Reduced 25.31%	11,506 $7,000
Q3 2023 Nov 15, 2023	SELL	$0.47 - $0.9 $893 - $1,710	-1,900 Reduced 10.98%	15,406 $9,000
Q1 2023 May 15, 2023	BUY	$0.42 - $0.75 $41 - $74	99 Added 0.58%	17,306 $7,000
Q4 2022 Feb 14, 2023	SELL	$0.54 - $9.8 $4,246 - $77,067	-7,864 Reduced 31.37%	17,207 $10,000
Q3 2022 Nov 14, 2022	BUY	$0.13 - $12.4 $41 - $3,955	319 Added 1.29%	25,071 $18,000
Q2 2022 Oct 27, 2022	SELL	$1.11 - $3.46 $235 - $733	-212 Reduced 0.85%	24,752 $36,000
Q2 2022 Aug 15, 2022	SELL	$1.11 - $3.46 $235 - $733	-212 Reduced 0.85%	24,752 $36,000
Q1 2022 Oct 27, 2022	BUY	$1.78 - $8.5 $377 - $1,802	212 Added 0.86%	24,964 $95,000
Q1 2022 May 13, 2022	SELL	$1.78 - $8.5 $12,951 - $61,846	-7,276 Reduced 22.57%	24,964 $95,000
Q4 2021 Feb 14, 2022	BUY	$7.3 - $11.24 $235,352 - $362,377	32,240 New	32,240 $252,000

529K

Ticker SABS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,030,900
Market Cap $133M
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.